Perrigo Company plc raised earnings guidance for the fiscal year 2022. For the year, the company raised net sales growth guidance to 8.5%-9.5% from 3.5%-4.5%, compared to the prior year, primarily due to the acquisition of HRA, which closed on April 29, 2022. The Company is also raising its fiscal 2022 organic growth range outlook from 7%-8% to 8%-9%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
31.82 USD | +1.74% | +3.33% | -1.10% |
Apr. 25 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
Apr. 25 | Perrigo Receives Binding Offer to Sell HRA Pharma Rare Diseases Business for Up to $295 Million | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.10% | 4.24B | |
+25.93% | 653B | |
+27.00% | 556B | |
-6.45% | 354B | |
+20.52% | 331B | |
+3.95% | 296B | |
+12.97% | 233B | |
+5.59% | 201B | |
-9.61% | 193B | |
-6.35% | 144B |
- Stock Market
- Equities
- PRGO Stock
- News Perrigo Company plc
- Perrigo Company plc Raises Earnings Guidance for the Fiscal Year 2022